TABLE 1.
Demographic and Clinical Characteristics at Baseline
| Characteristic | Overall Subjects (n 5 61) |
Genotype 1a (n 5 35) |
Genotype 1b (n 5 26) |
P Value |
|---|---|---|---|---|
| Male sex | 32 (52) | 20 (57) | 12 (47) | 0.39 |
| Age, years | 61 (58-65) | 61 (58-64) | 62.5 (57-67) | 0.24 |
| BMI, kg/m2 | 28 (25-33) | 28 (25-33) | 28 (26-31) | 0.62 |
| Race | ||||
| White | 31 (51) | 20 (57) | 11 (42) | 0.26 |
| Hispanic and Latino | 23 (37) | 10 (29) | 13 (50) | |
| Black and African American | 7 (11) | 5 (14) | 2 (8) | |
| Time after LT, years | 5.4 (1.9-8.4) | 3.7 (1.6-9.4) | 6.3 (3-8) | 0.93 |
| Kidney transplant | 3 (6) | 2 (5.7) | 1 (4) | >0.99 |
| Baseline HCV RNA, IU/mL | 2,722,473 (656,500-5,436,036) | 3,498,287 (954,960-7,473,198) | 1,602,793 (542,988-4,097,443) | 0.18 |
| HCV genotype 1a | 35 (57) | — | — | — |
| HCV genotype 1b | 26 (43) | — | — | — |
| Nonresponder or relapse to prior treatment | 42 (69) | 24 (69) | 18 (69) | >0.99 |
| Prior treatment stopped because of AEs | 13 (21) | 7 (20) | 6 (23) | >0.99 |
| Protease inhibitor–experienced | 5 (8) | 3 (8) | 2 (8) | 0.90 |
| METAVIR F0-F2 | 38 (62) | 23 (66) | 15 (58) | 0.59 |
| METAVIR F3-F4 | 23 (38) | 12 (34) | 11 (42) | |
| Hepatic decompensation | 8 (13) | 3 (9) | 5 (19) | 0.27 |
NOTE: Data are given as n (%) or median (IQR). Parametric or nonparametric (2 tailed Chi-square) analyses were performed as appropriate.